CORCEPT THERAPEUTICS INC (CORT) Financial Statements — Income, Balance Sheet, Cash Flow

Overview Financials Chart Business Summary Filings Ownership Valuation

Financial Statements — CORT

Balance Sheet

(in millions USD)

Metric	Q2 2026	Q1 2026	Q3 2025	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022	Q1 2022	Q3 2021	Q2 2021	Q1 2021
Cash & Equivalents	111.04	108.74	125.14	102.75	89.82	137.29	128.59	149.75	111.80	172.38	299.94	50.24	35.35	61.86	94.69	95.43	52.38
Short-term Investments	197.16	229.45	296.55	239.48	232.94	243.05	344.57	261.01	243.43	190.89	165.12	346.02	334.74	283.67	266.64	274.55	320.58
Accounts Receivable	76.92	39.07	69.63	64.57	61.82	59.72	53.84	61.52	34.63	32.55	32.56	29.41	28.16	27.18	26.51	27.62	22.20
Inventory	13.19	12.89	12.35	12.28	14.37	8.05	8.35	7.19	7.51	6.92	6.41	6.05	5.44	5.08	4.99	4.67	4.95
Total Current Assets	439.68	426.03	541.13	443.11	438.50	466.98	560.85	503.37	431.53	432.59	533.89	452.40	419.05	388.22	401.90	411.27	409.62
Property, Plant & Equipment	5.13	3.17	2.09	2.35	2.54	2.93	1.47	0.13	0.30	0.41	0.46	0.80	0.86	0.73	1.23	1.41	1.48
Total Non-current Assets*	449.03	388.85	282.48	358.61	407.95	317.28	153.71	152.57	162.50	92.04	83.96	80.85	77.32	79.90	183.50	157.21	142.77
Total Assets	888.70	814.88	823.61	801.72	846.46	784.26	714.56	655.94	594.02	524.63	617.85	533.26	496.36	468.12	585.40	568.48	552.40
Accounts Payable	14.91	33.31	34.45	23.53	27.95	18.58	19.48	12.56	16.71	7.98	11.22	8.18	8.25	9.27	6.56	9.22	6.97
Total Current Liabilities	153.80	149.19	172.27	144.66	143.07	126.22	100.75	97.20	121.87	93.06	78.86	53.07	49.06	57.24	44.76	45.40	40.60
Total Non-current Liabilities*	29.12	27.71	19.44	21.27	20.10	19.21	17.56	10.87	10.47	9.95	9.40	6.82	4.98	3.07	0.41	0.40	1.00
Total Liabilities	182.93	176.89	191.71	165.93	163.17	145.42	118.31	108.07	132.34	103.01	88.26	59.89	54.04	60.31	45.17	45.81	41.60
Retained Earnings	654.61	611.63	619.10	599.43	564.28	512.99	465.78	430.29	371.17	339.79	312.27	279.79	245.18	217.77	162.92	132.44	105.92
Total Stockholder Equity	705.78	637.99	631.90	635.79	683.29	638.84	596.24	547.86	461.68	421.61	529.58	473.36	442.33	407.81	540.23	522.67	510.80

* Derived from reported values

Income Statement

(in millions USD) (except per-share rows)

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021
Total Revenue	256.15	164.90	202.13	207.64	194.43	157.21	181.89	182.55	163.80	146.81	135.41	123.60	117.72	105.65	103.06	101.73	103.39	93.69	98.82	96.13
Cost of Revenue	4.06	2.88	2.55	4.60	3.43	2.40	2.96	2.87	2.52	2.54	1.88	1.65	1.57	1.39	1.48	1.34	1.32	1.25	1.35	1.27
Gross Profit	252.09	162.02	199.58	203.04	191.00	154.81	178.93	179.68	161.27	144.27	133.53	121.96	116.14	104.27	101.58	100.39	102.07	92.44	97.47	94.86
Research & Development	53.89	66.27	64.86	68.85	60.47	60.74	70.30	59.34	58.75	58.51	54.71	45.52	43.28	40.85	36.75	33.29	32.83	28.12	28.52	28.09
Selling, General & Admin	156.90	145.36	130.24	123.98	103.85	90.66	83.37	73.75	66.94	56.27	47.15	45.26	43.28	48.56	42.32	35.16	37.81	37.55	32.28	30.53
Total Operating Expenses	210.79	211.62	195.09	192.82	164.32	151.40	153.67	133.08	125.68	114.77	101.86	90.78	86.56	89.42	79.08	68.46	70.64	65.67	60.80	58.62
Operating Income	41.30	(49.60)	4.49	10.22	26.68	3.42	25.26	46.60	35.59	29.50	31.67	31.18	29.58	14.85	22.50	31.93	31.43	26.77	36.66	36.23
Pretax Income	45.93	(44.71)	9.91	15.24	31.69	9.62	31.96	52.94	41.60	34.99	36.81	36.39	32.93	18.43	24.28	33.00	32.06	26.85	36.74	36.30
Tax Provision	2.94	(12.95)	(14.38)	(4.42)	(3.46)	(10.93)	1.22	5.73	6.11	7.23	5.45	5.01	5.40	2.56	7.68	(1.60)	4.65	4.05	4.68	5.83
Net Income	42.99	(31.76)	24.29	19.67	35.15	20.55	30.75	47.21	35.49	27.76	31.36	31.38	27.53	15.88	16.60	34.61	27.41	22.80	32.05	30.47
Basic EPS	0.40	(0.30)	0.24	0.19	0.33	0.19	0.29	0.45	0.34	0.27	0.29	0.31	0.27	0.15	0.15	0.32	0.26	0.22	0.28	0.26
Diluted EPS	0.36	(0.30)	0.20	0.16	0.29	0.17	0.25	0.41	0.32	0.25	0.27	0.28	0.25	0.14	0.13	0.30	0.24	0.20	0.26	0.24

Cash Flow Statement

(in millions USD)

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021
Operating Cash Flow	33.54	(16.77)	38.45	54.48	43.94	5.13	59.30	73.83	41.18	23.76	5.89	52.91	42.29	25.96	33.39	33.65	18.04	35.25	49.43	48.70
Capital Expenditures	2.53	0.20	0.05	0.00	0.06	0.10	0.12	1.64	0.42	--	0.00	0.04	0.10	0.00	0.03	0.35	0.02	0.01	0.07	0.16
Free Cash Flow*	31.02	(16.97)	38.40	54.48	43.88	5.02	59.18	72.19	40.77	--	5.89	52.87	42.18	25.96	33.36	33.30	18.02	35.24	49.36	48.55
Investing Cash Flow	(29.24)	4.54	(11.84)	14.65	70.13	(3.17)	(64.36)	(44.04)	(60.19)	(9.01)	17.10	(109.57)	(24.10)	207.48	(17.24)	(4.79)	(41.80)	(50.50)	140.47	(25.80)
Financing Cash Flow	(2.04)	0.76	(31.22)	(46.41)	(102.93)	(39.80)	(4.56)	(21.09)	(2.15)	(0.54)	0.77	(3.92)	(145.75)	0.18	(0.06)	(13.96)	(2.76)	(0.51)	(206.97)	(23.64)

* Derived from reported values